勘误：利妥昔单抗维持治疗的获益与滤泡性淋巴瘤患者的滤泡性淋巴瘤国际预后指数相关。
Erratum: Benefit of rituximab maintenance is associated with Follicular Lymphoma International Prognostic Index in patients with follicular lymphoma.
出版信息
Blood Sci. 2023 Aug 3;5(3):219. doi: 10.1097/BS9.0000000000000164. eCollection 2023 Jul.
Abstract
[This corrects the article DOI: 10.1097/BS9.0000000000000144.].
摘要
[本文更正了文章的数字对象标识符：10.1097/BS9.0000000000000144。]
相似文献
1
Erratum: Benefit of rituximab maintenance is associated with Follicular Lymphoma International Prognostic Index in patients with follicular lymphoma.勘误：利妥昔单抗维持治疗的获益与滤泡性淋巴瘤患者的滤泡性淋巴瘤国际预后指数相关。
Blood Sci. 2023 Aug 3;5(3):219. doi: 10.1097/BS9.0000000000000164. eCollection 2023 Jul.
2
Benefit of rituximab maintenance is associated with Follicular Lymphoma International Prognostic Index in patients with follicular lymphoma.利妥昔单抗维持治疗的获益与滤泡性淋巴瘤患者的滤泡性淋巴瘤国际预后指数相关。
Blood Sci. 2022 Dec 9;5(2):118-124. doi: 10.1097/BS9.0000000000000144. eCollection 2023 Apr.
3
A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts.基于基因表达谱的滤泡性淋巴瘤患者预后预测评分：三队列回顾性训练和验证分析。
Lancet Oncol. 2018 Apr;19(4):549-561. doi: 10.1016/S1470-2045(18)30102-5. Epub 2018 Feb 20.
4
[Prognostic Significance of Follicular Lymphoma International Prognostic Index 2 (FLIPI2) in Follicular Lymphoma Patients Treated with Rituximab Maintenance].利妥昔单抗维持治疗的滤泡性淋巴瘤患者中滤泡性淋巴瘤国际预后指数2（FLIPI2）的预后意义
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2017 Apr;25(2):426-430. doi: 10.7534/j.issn.1009-2137.2017.02.021.
5
The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study.MLH1基因分型可识别出一组无法从多柔比星治疗中获益的滤泡性淋巴瘤患者：FIL-FOLL研究。
Haematologica. 2015 Apr;100(4):517-24. doi: 10.3324/haematol.2014.108183. Epub 2015 Jan 16.
6
The incidence of biopsy-proven transformation in follicular lymphoma in the rituximab era. A retrospective analysis from the Czech Lymphoma Study Group (CLSG) database.利妥昔单抗时代滤泡性淋巴瘤经活检证实的转化发生率。来自捷克淋巴瘤研究组（CLSG）数据库的回顾性分析。
Ann Hematol. 2018 Apr;97(4):669-678. doi: 10.1007/s00277-017-3218-0. Epub 2018 Jan 9.
7
Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials.利妥昔单抗维持治疗滤泡性淋巴瘤患者：随机试验的系统评价和荟萃分析
J Natl Cancer Inst. 2009 Feb 18;101(4):248-55. doi: 10.1093/jnci/djn478. Epub 2009 Feb 10.
8
Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study.利妥昔单抗生物类似药与原研利妥昔单抗用于既往未治疗的晚期滤泡性淋巴瘤患者（ASSIST-FL）：一项确证性3期双盲随机对照研究的主要结果
Lancet Haematol. 2017 Aug;4(8):e350-e361. doi: 10.1016/S2352-3026(17)30106-0. Epub 2017 Jul 14.
9
Rituximab Maintenance Versus Observation After Immunochemotherapy (R-CHOP, R-MCP, and R-FCM) in Untreated Follicular Lymphoma Patients: A Randomized Trial of the Ostdeutsche Studiengruppe Hämatologie und Onkologie and the German Low-Grade Lymphoma Study Group.利妥昔单抗维持治疗与观察在初治滤泡性淋巴瘤患者免疫化疗（R-CHOP、R-MCP和R-FCM）后的比较：德国东部血液学与肿瘤学研究小组和德国低度淋巴瘤研究小组的一项随机试验
Hemasphere. 2021 Jun 23;5(7):e600. doi: 10.1097/HS9.0000000000000600. eCollection 2021 Jul.
10
Characteristics of follicular and mantle cell lymphoma in Brazil: prognostic impact of clinical parameters and treatment conditions in two hospitals.巴西滤泡性和套细胞淋巴瘤的特征：两家医院临床参数和治疗条件的预后影响
Hematol Transfus Cell Ther. 2018 Oct-Dec;40(4):343-353. doi: 10.1016/j.htct.2018.02.004. Epub 2018 Apr 18.
本文引用的文献
1
Benefit of rituximab maintenance is associated with Follicular Lymphoma International Prognostic Index in patients with follicular lymphoma.利妥昔单抗维持治疗的获益与滤泡性淋巴瘤患者的滤泡性淋巴瘤国际预后指数相关。
Blood Sci. 2022 Dec 9;5(2):118-124. doi: 10.1097/BS9.0000000000000144. eCollection 2023 Apr.
Zotero 插件